# Tesaglitazar

**Cat. No.:** HY-17444

**CAS No.:** 251565-85-2

**Molecular Formula:** $C_{20}H_{24}O_7S$

**Molecular Weight:** 408.47

**Target:** PPAR

**Pathway:** Cell Cycle/DNA Damage; Vitamin D Related/Nuclear Receptor

**Storage:** -20°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



## SOLVENT & SOLUBILITY

**In Vitro**

DMSO : 200 mg/mL (489.63 mM; ultrasonic and warming and heat to 60°C)

| Preparing Stock Solutions | Solvent / Mass / Concentration | 1 mg | 5 mg | 10 mg |
|---|---|---|---|---|
| | 1 mM | 2.4482 mL | 12.2408 mL | 24.4816 mL |
| | 5 mM | 0.4896 mL | 2.4482 mL | 4.8963 mL |
| | 10 mM | 0.2448 mL | 1.2241 mL | 2.4482 mL |

Please refer to the solubility information to select the appropriate solvent.

## BIOLOGICAL ACTIVITY

**Description**

Tesaglitazar is a dual peroxisome proliferator-activated receptor (PPAR) alpha/gamma agonist that is more potent on PPARγ than on PPARα, with $EC_{50}$s of 13.4 μM and 3.6 μM for rat PPARα and human PPARα, respectively, and approximately 0.2 μM for both rat and human PPARγ. Tesaglitazar induces interstitial mesenchymal cell DNA synthesis and fibrosarcomas in subcutaneous tissues in rats[1].

**$IC_{50}$ & Target**

EC50: 13.4 μM (rat PPARα), 3.6 μM (human PPARα), 0.2 μM (PPARγ)[1]

## REFERENCES

[1]. Hellmold H, et al. Tesaglitazar, a PPARalpha/gamma agonist, induces interstitial mesenchymal cell DNA synthesis and fibrosarcomas in subcutaneous tissues in rats. Toxicol Sci. 2007 Jul;98(1):63-74.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA